SCM Lifescience Balance Sheet Health
Financial Health criteria checks 2/6
SCM Lifescience has a total shareholder equity of ₩11.8B and total debt of ₩3.6B, which brings its debt-to-equity ratio to 30.8%. Its total assets and total liabilities are ₩18.9B and ₩7.1B respectively.
Key information
30.8%
Debt to equity ratio
₩3.63b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩2.28b |
| Equity | ₩11.79b |
| Total liabilities | ₩7.09b |
| Total assets | ₩18.87b |
Financial Position Analysis
Short Term Liabilities: A298060's short term assets (₩3.6B) exceed its short term liabilities (₩2.9B).
Long Term Liabilities: A298060's short term assets (₩3.6B) do not cover its long term liabilities (₩4.2B).
Debt to Equity History and Analysis
Debt Level: A298060's net debt to equity ratio (11.4%) is considered satisfactory.
Reducing Debt: A298060's debt to equity ratio has increased from 21.8% to 30.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A298060 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A298060 has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.1% each year.